Endometriosis (EM)
is a hormone-dependent gynecological disease
associated with chronic pelvic pain and altered immuno-inflammatory
processes. It shares some cancer-like characteristics such as increased
proline biosynthesis and activated glutaminolysis. Both proline and
glutamine are interconvertible metabolically, and studies have shown
their roles in cancer cell metabolic reprogramming, redox homeostasis,
occurrence/development of endometrial carcinoma, and its further progression
toward the malignant state. So based on this, we hypothesized that
the circulatory proline to glutamine ratio (PQR) would be altered
in EM and may serve as an indicative biomarker to improve the clinical
diagnosis of EM. In present study, the circulatory-PQR levels were
estimated for 39 EM patients and 48 age matched healthy female subjects
using 800 MHz NMR spectroscopy. Among 39 EM patients, 15 were in the
clinical stages I to II and referred to here as moderate EM (MEM)
patients and 24 were in the clinical stages III to IV and referred
here as severe EM (SEM) patients. The circulatory-PQR levels were
significantly increased in EM patients (0.99 ± 0.13 μM
in MEM; 1.39 ± 0.22 μM in SEM) compared to normal control
(NC) subjects (0.52 ± 0.05 μM in NC). Further, the circulatory
PQR levels exhibit the highest diagnostic potential with area under
receiver operating characteristic (AUROC) curve values equal to 0.87
± 0.04 [95%CI = 0.79–0.96] for MEM and 0.89 ± 0.04
[95% CI = 0.82–0.96] for SEM. These results suggested that
circulatory-PQR has significant potential to serve as a noninvasive
biomarker for diagnostic/prognostic screening of EM and further underscored
the importance of these two nonessential amino acids (proline and
glutamine) in cancer metabolism.